FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Andersen Eric

2. Date of Event Requiring Statement (MM/DD/YYYY)
9/18/2019 

3. Issuer Name and Ticker or Trading Symbol

MERRIMACK PHARMACEUTICALS INC [MACK]

(Last)        (First)        (Middle)

5900 WILSHIRE BOULEVARD, SUITE 650

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          _____ 10% Owner
_____ Officer (give title below)        ___X___ Other (specify below)
/ See Remarks

(Street)

LOS ANGELES, CA 90036      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)

 

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 666327 I See footnote (1)
Common Stock 176586 I See footnote (2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) The shares are directly held by WSP. The general partner of the Funds is Western Standard. The managing member of Western Standard and the portfolio manager to the Funds is Mr. Andersen. Each of Western Standard and Mr. Andersen disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
(2) The shares are directly held by WSP QP. The general partner of the Funds is Western Standard. The managing member of Western Standard and the portfolio manager to the Funds is Mr. Andersen. Each of Western Standard and Mr. Andersen disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Remarks:
As a result of an agreement among the persons listed below to vote their respective shares of Common Stock jointly, such persons have formed a "group" under Section 13(d)(1) of the Exchange Act. In addition to Mr. Andersen, Western Standard, LLC ("Western Standard"), Western Standard Partners, LP ("WSP") and Western Standard Partners QP, LP ("WSP QP" and together with WSP, the "Funds") (collectively, the "Western Standard Parties"), the members of this group are Noah G. Levy, Newtyn Management, LLC, Newtyn Partners, Newtyn TE Partners, LP, Newtyn Capital Partners, LP, and Ledo Capital, LLC (collectively, the "Newtyn Parties" and collectively with the Western Standard Parties, the "13D Group").
As a member of the 13D Group, each Western Standard Party would be deemed to beneficially own the aggregate amount of the Common Stock that each of the 13D Group members beneficially owns, in which case it or he would be deemed to beneficially own 2,016,079 shares of Common Stock. However, none of the Western Standard Parties have the ability to direct the acquisition or disposition or, except through the Cooperation Agreement, voting of the securities held by Newtyn Parties, and none of the Newtyn Parties have the ability to direct the acquisition or disposition or, except through the Cooperation Agreement, voting of the securities held by the Western Standard Parties. As members of the 13D Group, the combined holdings of the Western Standard Parties and the Newtyn Parties would result in each Western Standard Party having voting power equivalent to a combined beneficial ownership of 15.1% of the Issuer's outstanding Common Stock for voting purposes. Each Western Standard Party disclaims beneficial ownership of the shares beneficially owned by the 13D Group except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Andersen Eric
5900 WILSHIRE BOULEVARD, SUITE 650
LOS ANGELES, CA 90036
X

See Remarks
Western Standard LLC
5900 WILSHIRE BOULEVARD, SUITE 650
LOS ANGELES, CA 90036



See Remarks
WESTERN STANDARD PARTNERS LP
5900 WILSHIRE BOULEVARD, SUITE 650
LOS ANGELES, CA 90036



See Remarks
Western Standard Partners QP, L.P.
5900 WILSHIRE BOULEVARD, SUITE 650
LOS ANGELES, CA 90036



See Remarks

Signatures
/s/ Eric D. Andersen9/27/2019
**Signature of Reporting PersonDate

Western Standard, LLC; /s/ Eric D. Andersen, Managing Member9/27/2019
**Signature of Reporting PersonDate

Western Standard Partners, LP; By: Western Standard, LLC, General Partner; /s/ Eric D. Andersen, Managing Member9/27/2019
**Signature of Reporting PersonDate

Western Standard Partners QP, LP; By: Western Standard, LLC, General Partner; /s/ Eric D. Andersen, Managing Member9/27/2019
**Signature of Reporting PersonDate

Merrimack Pharmaceuticals (NASDAQ:MACK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Merrimack Pharmaceuticals Charts.
Merrimack Pharmaceuticals (NASDAQ:MACK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Merrimack Pharmaceuticals Charts.